Conference Reports for NATAP

Back

AASLD The Liver Meeting November 2020     AASLD Selected Highlights - HCV Elimination, Screening, Treatment - (05/25/21)   The Future of HCV Vaccine Development - (06/01/21)   Shelter-Based Integrated HCV Care Model is Effective in Scaling up HCV Testing and Treatment in Homeless Clients Across Two Large Urban Settings - (02/01/21)   NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID19 INFECTION - INITIAL UK BIOBANK OBSERVATIONS - (02/01/21)   AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (01/08/21)   Efficacy and safety of subcutaneous semaglutide once-daily versus placebo in patients with nonalcoholic steatohepatitis Semaglutide Resolves NASH in Big Placebo-Controlled Trial - (01/07/21)   HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)   PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)   GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)   AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)   Distinct lipidomic signatures between persons living with HIV and seronegative persons: combined analysis of the ACTG 5260s and the MACS/WIHS Combined Cohort Study - (12/18/20)   Infant Outcomes in HIV/Hepatitis B Co-Infected Women Initiating ART in the Promoting Maternal and Infant Survival Everywhere Study - (12/10/20)   Safety And HBV Efficacy Of Antiretroviral Therapy In Women With HIV And HBV In The Promoting Maternal And Infant Survival Everywhere Study (PROMISE) - (12/10/20)   Novel Paradigms of HCV Care Delivery - Treatment Beyond the Specialty Clinic - (12/10/20)   NAFLD AND ALCOHOL-RELATED LIVER DISEASE ARE PRIMARY DRIVERS OF CURRENT AND FUTURE CAUSES OF CIRRHOSIS AMONG WOMEN IN NORTH AMERICA - (12/03/20)   SEMAGLUTIDE TREATMENT IN SUBJECTS WITH NAFLD: EFFECTS ASSESSED BY MAGNETIC RESONANCE ELASTOGRAPHY AND MAGNETIC RESONANCE IMAGING PROTON DENSITY FAT FRACTION - (12/02/20)   RESOLVE-IT Phase 3 of Elafibranor in NASH: Final Results of the Week 72 Interim Surrogate Efficacy Analysis - (12/02/20)   HCC, Decompensation, Alcohol, Tied to Death in Liver Patients With COVID-19 - Mark Mascolini (12/01/20)   Predictors Of Outcomes Of Covid-19 In Patients With Chronic Liver Disease: US Multi-center Study. - (12/01/20)   A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) - (12/01/20)   What Are the Current Treatment Options for our Patients with NAFLD/NASH ? - (12/01/20)   Patient-Reported Outcomes in Patients with Chronic Hepatitis C: Data from the Global Liver Registry - (12/01/20)   FIB -4 and FibroScan Can Identify Patients With Nonalcoholic Fatty Liver Disease Who Are at Risk of Liver-Related Events: Results of a Longitudinal Analysis With Comparison With Liver Biopsy - (12/01/20)   Identification of Undiagnosed NASH: Development and Application of a Real-world Prediction Model - (12/01/20)   ECONOMIC BURDEN OF NASH-ASSOCIATED CIRRHOSIS: US PAYOR'S PERSPECTIVE - (12/01/20)   Noninvasive Assessments to Identify Patients With Advanced Fibrosis Due to NASH: Screened Population From the REGENERATE Trial - (12/01/20)   Evaluation of Obeticholic Acid Efficacy in Patients With NASH Who Were Monitored Using Noninvasive Tests: A Post Hoc Analysis of the REGENERATE Trial - (12/01/20)   Prediction accuracy of the NASHmap algorithm designed to screen for presence of NASH - (12/01/20)   Prediction accuracy of the NASHmap algorithm designed to screen for presence of NASH - (12/01/20)   In 20-Year NAFLD Study, Lean Have Higher Death Rate Than Obese - Mark Mascolini (12/01/20)   OPPORTUNITIES FOR EARLY DIAGNOSIS OF UNRECOGNIZED CIRRHOSIS IN THE DEPARTMENT OF VETERANS AFFAIRS - (11/28/20)   AFFORDABLE CARE ACT MEDICAID EXPANSION IMPROVED LIVER TRANSPLANT WAITLIST PLACEMENT AND SLOWED RACIAL DISPARITIES - (11/28/20)   Treatment As Prevention: Addressing HCV in Persons Who Inject Drugs (PWID) - (11/28/20)   CONTINUED INEQUITIES IN THE HEPATITIS C CASCADE OF CARE EXPERIENCED BY PEOPLE WHO INJECT DRUGS IN BRITISH COLUMBIA IN 2019: A POPULATION-LEVEL LINKED DATA STUDY - (11/28/20)   The impact of direct acting antiviral treatments on all-cause, liver- and drug-related mortality in a large population-based cohort study - (11/28/20)   WOMEN AND THE 2019 HEPATITIS C CASCADE OF CARE: FINDINGS FROM THE BC-HEPATITIS TESTERS COHORT - (11/28/20)   DAAs Improve HCC Liver Transplant Survival - Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >18,000w patients: HCC Liver Transplant Survival No Longer Worse With HCV Than HBV - Mark Mascolini (11/28/20)   Elbasvir/Grazoprevir in Children Aged 3 to <18 Years With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: Final Results From an Iterative Pharmacokinetic Modeling Study - (11/28/20)   Progression of the FIB-4 Index among Patients with Chronic HCV Infection - (11/28/20)   BILE DUCT INJURY AND SEVERE CHOLESTASIS IN PATIENTS RECOVERING FROM SEVERE COVID-19: A NOVEL ENTITY OF COVID-ASSOCIATED-CHOLANGIOPATHY - (11/28/20)   Early phase implementation of routine opt out hepatitis C testing in the Philadelphia jail system - (11/28/20)   Liver Transplant Evaluation Within 30 Days Improves Pretransplant Survival - Mark Mascolini (11/28/20)   Risk of severe acute liver injury among initiators of potentially hepatotoxic drugs. - Mark Mascolini (11/28/20)   Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study - (11/28/20)   Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study - (11/24/20)   Systematic Review and Meta-analysis of FIB-4 for the Diagnosis of Advanced Fibrosis due to Nonalcoholic Steatohepatitis - (11/24/20)   Final analysis of a 24-week, randomized, double blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - Mark Mascolini (11/24/20)   Novel, first-in-class, fatty acid synthase (FASN) inhibitor, TVB-2640 demonstrates clinically significant reduction in liver fat by MRI-PDFF, and ALT in NASH: a phase 2 randomized placebo controlled TRIAL (FASCINATE-1). - Mark Mascolini (11/24/20)   Safety and Drug-Drug Interaction of Tropifexor in Combination With Licogliflozin in Healthy but Overweight to Obese Subjects in Support of a Ph2b Combination Study ELIVATE - (11/24/20)   LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: FULL STUDY ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2A STUDY - (11/24/20)   Cilofexor and Firsocostat in Combination Lead to Greater Reductions in Serum Bile Acids, Which Are Associated With Treatment Response in Patients With Advanced Fibrosis Due to NASH - (11/24/20)   Combination Treatment With Cilofexor and Firsocostat Normalizes Cell Death Marker Cytokeratin 18 in Patients With Advanced Fibrosis Due to NASH - (11/24/20)   North America's Largest Meta-Analysis on the Prevalence of NAFLD, NASH, and Advanced Fibrosis (F3-F4) - (11/24/20)   Validation of a Machine Learning-Based Approach (DELTA Liver Fibrosis Score) for the Assessment of Histologic Response in Patients With Advanced Fibrosis Due to NASH - (11/24/20)   Clinical characteristics used for machine learning identification of fast progressors among patients with NASH - (11/24/20)   A phase 2, randomized, double-blind, placebo-controlled dose-finding study of the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor (A3AR) agonist, in treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). - A3AR Agonist Improves NAFLD-Related Variables in Phase 2 Trial - (11/24/20)   Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study - (11/24/20)   Survival After Liver Transplant Similar With NASH and Other Causes - Mark Mascolini (11/24/20)   Obesity Plus High Liver Fat Boost Odds of Hospital Admission With Severe COVID-19 -Mark Mascolini (11/24/20)   Can low liver fat be bad for your heart? Visceral Fat & Heart Disease - (11/24/20)   Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)   Lipid Management in a 24-Week, Randomized, Double-Blind, Placebo-Controlled Study of Aldafermin (NGM282) - (11/23/20)   Aldafermin (NGM282) Produces Greater Anti-Fibrotic Response in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/23/20)   Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (11/23/20)   Testosterone Helps Diet and Exercise Improve Sarcopenia in Men With Cirrhosis - Mark Mascolini (11/23/20)   Change in lipid markers throughout early adulthood is associated with prevalent NAFLD in mid-life: the coronary artery risk development in young adults (CARDIA) study - Mark Mascolini (11/23/20)   Impact of Pretreatment Plasma HBV DNA Levels on the Rate of ALT Normalization During Antiviral Therapy With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B - (11/23/20)   Amino Acid Substitutions in the Inhibitor Binding Pocket of HBV Core Protein Confer Differential Changes in Susceptibility to Three Generations of HBV Core Inhibitors - (11/23/20)   Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment - (11/23/20)   Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study - (11/23/20)   HBV RNAi INHIBITOR RG6346 IN PHASE 1b-2a TRIAL WAS SAFE, WELL-TOLERATED, AND RESULTED IN SUBSTANTIAL AND DURABLE REDUCTIONS IN SERUM HBsAg LEVELS - (11/23/20)   Short-term therapy with GSK3228836 in chronic hepatitis B (CHB) patients results in reductions in HBcrAg and HBV RNA: Phase 2a, randomized, double-blind, placebo-controlled study - (11/23/20)   Changes in Viral Antigens are More Strongly Associated with HBV pgRNA than HBV DNA in Studies of Vebicorvir and NrtI in Treatment-naïve Patients with Chronic HBV Infection - (11/23/20)   FUNCTIONAL CURE OF CHRONIC HEPATITIS B IS ASSOCIATED WITH CO-OCCURRENCE OF HBsAg/anti-HBsIMMUNE COMPLEXES WITH ALT FLARES, AND SEROCONVERSION TO NEUTRALISING anti-HBs - (11/23/20)   Impact of HBV on Patients - A Qualitative Literature Review to Build a Patient-Focused Outcome Measurement Strategy for Chronic Hepatitis B - (11/23/20)   Timing of Administration of Anti-PD-1 is Important to Increase HBV-specific Immune Responses in AAV-HBV Mice - (11/23/20)   Impact of Coadministration With or Without Food on the 96-Week Efficacy and Safety of TAF in Virally Suppressed Chronic HBV Patients Switched From Tenofovir Disoproxil Fumarate to TAF - (11/20/20)   Risk of HCC in Patients With HBV Infection With and Without HIV Coinfection: a US Administrative Claims Analysis - (11/20/20)   MACHINE LEARNING BASED QUANTIFICATION OF HISTOLOGY FEATURES FROM PATIENTS TREATED FOR CHRONIC HEPATITIS B IDENTIFIES FEATURES ASSOCIATED WITH VIRAL DNA SUPPRESSION AND HBEAG LOSS - (11/20/20)   POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS - (11/20/20)   Viral Sequence Analysis of Chronic Hepatitis B (CHB) Patients Treated with the Capsid Assembly Modulator (CAM-N) JNJ-56136379 (JNJ-6379) as Monotherapy in the JADE Phase 2a Study - (11/20/20)   Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection - (11/20/20)   Association of aspirin with hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. - Mark Mascolini (11/20/20)   HBsAg loss is higher among Caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study) - Mark Mascolini (11/20/20)   HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels - (11/20/20)   The microbiome changes induced by bariatric surgery protects against obesity and nonalcoholic fatty liver disease by decreasing gastric inhibitory protein and increasing hepatic NKT cell expression - Mark Mascolini (11/20/20)   A Random Forest Classifier Based on a 30-Gene Signature Distinguishes Patients With Bridging Fibrosis From Those With Cirrhosis Due to NASH (11/20/20)   Fc-FGF21 Fusion Protein Cuts Liver Fat, Improves Fibrosis in 4-Arm NASH Trial - Mark Mascolini (11/20/20)   Low Liver Fat Tied to Higher CHD Risk in Viscerally Obese People - Mark Mascolini (11/20/20)   COST-EFFECTIVENESS OF ANTENATAL RESCREENING AMONG PREGNANT WOMEN FOR HEPATITIS C IN THE UNITED STATES (11/20/20)   HEPATITIS C SCREENING IN THE GENERAL POPULATION IN A FRENCH CITY: A NEEDLE IN A HAYSTACK (11/20/20)   State Policies Limiting Progress Towards HCV Elimination in the U.S. (11/20/20)   Use of antipsychotic medication in active drug users, patients receiving opioid substitution therapy (OST) and HCV patients (11/20/20)   High Rates Of HCV Reinfection And Retreatment In A Cohort Of PWID With HCV Cure: Two Year Follow Up Data From The ANCHOR Study (11/20/20)   POINT-OF-CARE HEPATITIS C TESTING AND TREATING STRATEGY IN PEOPLE WHO INJECT DRUGS IN HARM REDUCTION AND ADDICTION CENTERS FOR HEPATITIS C ELIMINATION (11/19/20)   Time from diagnosis to treatment in vulnerable populations versus general population: Do we test-and-treat our HCV patients in the same way? (11/19/20)   MICROELIMINATION BEYOND PRISON WALLS: SUBJECTS SERVING NON-CUSTODIAL SENTENCES, SCREENING AND IMMEDIATE ASSISTED TREATMENT WITH "NAVIGATOR" FIGURE AND TELEMEDICINE (11/19/20)   Addressing Barriers to HCV Elimination in Italy: Health Care Resource Utilization and Cost Savings From Using 8 vs 12 Weeks of Glecaprevir/Pibrentasvir Therapy (11/19/20)   Preliminary results of the NORTHERN-HCV study assessing the impact of a simplified care model on direct-acting antivirals treatment for RNA-positive hepatitis C virus patients: A retrospective review of the TrueNorth Medical Centres database in Ontario, Canada (11/19/20)   Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies (11/19/20)   Prevalence of Undiagnosed Hepatitis C Virus Infected Individuals Estimated by Regional Mathematical-Modelling in Italy (11/19/20)   The "Keep It Simple and Safe" Approach to HCV Treatment: Primary Outcomes from the ACTG A5360 (MINMON) Study (11/19/20)   HCC Incidence Gains in US Slowed in Urban But Not Rural Areas. - Mark Mascolini (11/19/20)   Abnormal liver function tests on admission are associated with increased mortality in hospitalized patients with COVID-19: Results from a large Latin American cohort. (11/19/20)   SARS-CoV-2 Rewires Lipid and Metabolic Profiles, Posing Heart and Liver Risks - Mark Mascolini (11/19/20)   Abnormal Liver Tests at COVID Hospitalization Tied to Severe Disease, Death - Mark Mascolini (11/19/20)   HCC, Decompensation, Alcohol, Tied to Death in Liver Patients With COVID-19 - Mark Mascolini (11/19/20)   Longitudinal real world study on estimated glomerular filtration rate (eGFR) changes in entecavir (ETV) versus tenofovir disoproxil fumarate (TDF)-treated chronic hepatitis B patients: a Real-B Study. - Mark Mascolini (11/18/20)   Safety and Efficacy of 24 Weeks of Treatment With Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B: a Phase 2 Study - (11/18/20)   Tenofovir Disoproxil Fumarate Treatment Reduces the Number of Transcriptionally Active Viral Integrations in Chronically Infected HBV patients - (11/18/20)   Safety and Efficacy of 24 Weeks of Treatment With Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B: a Phase 2 Study - (11/18/20)   COUNTRY AND WHO REGIONAL TRENDS FOR HEPATITIS B VIRUS (HBV) MORTALITY, 1990-2019: AN ANALYSIS OF THE GLOBAL BURDEN OF DISEASE (GBD) STUDY - (11/18/20)   Tenofovir alafenamide to prevent perinatal hepatitis B transmission in mothers with high viral load: a multicenter, prospective, observational study. - Mark Mascolini - (11/18/20)   Real world single center experience on the efficacy of stopping long term nucleos(t)ide analog therapy in patients with chronic hepatitis B. - Mark Mascolini (11/18/20)   Long term nucleos(t)ide analogue therapy reduced the extent of HBV DNA integration in chronic hepatitis B patients - Mark Mascolini (11/18/20)   Real World Single Centre Experience on the Efficacy of Stopping Long Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B - (11/18/20)   Long-term Follow-up of Safety and Efficacy of Sofosbuvir-Based HCV DAAs in Pediatric Patients - (11/18/20)   Real world single center experience on the efficacy of stopping long term nucleos(t)ide analog therapy in patients with chronic hepatitis B - (11/18/20)   Tenofovir alafenamide fumarate therapy for the prevention of hepatitis B vertical transmission in highly viremic mothers with chronic hepatitis B - Mark Mascolini (11/18/20)   Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)   Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)   The Lipidomics of HIV-related NAFLD - (11/17/20)   Dietary Risks for Liver Related Morality Among Nonalcoholic Fatty Liver Disease (NAFLD) - (11/17/20)   Treatment with Growth Hormone-Releasing Hormone Analog Reduces VEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)   Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)   Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)   Periodontitis is associated with chronic liver disease in a population-based cohort of US adults - Mark Mascolini (11/17/20)   Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response (SVR) with direct-acting antivirals - Mark Mascolini (11/17/20)   Can Hepatitis C Treatment with Direct-Acting Antivirals be Cost Saving? A Global Modeling Study of 158 Countries - (11/17/20)   A Multisite Randomized Pragmatic Trial of Patient-Centered Models of Hepatitis C Treatment for People Who Inject Drugs: The HERO Study - Hepatitis C Real Options - (11/16/20)   Hepatitis C elimination in Europe - (11/16/20)   Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes - (11/16/20)   Patient characteristics and efficacy of pangenotypic direct-acting antiviral regimens among a cohort of chronic hepatitis C patients receiving routine clinical care in the U.S. - (11/16/20)   Low adherence to infant HCV testing guidelines among pregnant women with HCV cirrhosis - (11/16/20)   Outcomes following resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. - Mark Mascolini - (11/16/20)   Predictors and outcomes of steroid-refractory immune checkpoint inhibitor hepatitis. - Mark Mascolini - (11/16/20)   Addition of structured psychosocial assessment and intervention to interdisciplinary Hepatitis C team increases treatment uptake: Results of the prospective, randomized, controlled CARE-C trial - (11/16/20)   Determining Feasibility of Hepatitis C Elimination in the United States Using a Simulation Model - (11/16/20)   Age-Related Co-Morbidities and Polypharmacy in HCV-Infected Patients With Substance Use Disorders Treated With G/P: A Real-World Analysis From 9 Countries - (11/16/20)   Drug-drug interactions (DDIs) in Italian patients with chronic hepatitis C (HCV) treated with pangenotypic direct acting agents (pDAAs): focus on cardiovascular and central nervous system co-medications - (11/16/20)   Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Children and Adolescents Aged 3 to 17 Years Old Through 24 Weeks Posttreatment - (11/16/20)   Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adolescents With Chronic Hepatitis C Virus Infection - (11/16/20)   Active Drug Use Is Not Associated with Treatment Failure Among PWID Patients With Variable Adherence to HCV Treatment - (11/16/20)   Variable Adherence To HCV Treatment Among People Who Inject Drugs Treated with 8 Versus 12 Weeks of Antiviral Therapy Resulted In High Rates of SVR - (11/16/20)   A hospital free of Hepatitis C: Hepatitis C virus screening program in an Emergency Department of a tertiary hospital of a high-income country. (Preliminary results) - (11/16/20)   Barriers to Hepatitis C Virus Elimination in Germany in Patients Receiving Opioid Substitution Therapy - (11/16/20)   Positive Predictive Value of SVR4 in Patients Who Achieved SVR12 From Phase 2 and 3 Clinical Trials With Glecaprevir/Pibrentasvir - (11/16/20)   All Adult HCV Testing Global and US Implementation - (11/16/20)   Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study - (11/13/20)   Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies - (11/13/20)   POINT-OF-CARE HEPATITIS C TESTING AND TREATING STRATEGY IN PEOPLE WHO INJECT DRUGS IN HARM REDUCTION AND ADDICTION CENTERS FOR HEPATITIS C ELIMINATION - (11/13/20)   HCV elimination in homeless patients is possible: a pooled real-world analysis of homeless patients with HCV treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks - (11/13/20)   The value of sofosbuvir/velpatasvir (SOF/VEL) as a pangenotypic and panfibrotic HCV treatment in implementing a test-and-treat strategy in prisons: real-world care management from 6 countries - (11/13/20)   Integrated Efficacy and Safety Analysis of Genotypes 1-6 Treatment-Naïve, Non-Cirrhotic, and Compensated Cirrhotic Hispanic/Latino Patients Who Received 8 Weeks of Glecaprevir/Pibrentasvir - (11/13/20)   The risk of HCV recurrence in HCV infected patients treated with DAA after achieving a sustained virological response: a comprehensive analysis - (11/13/20)   ELIMINATING HEPATITIS C: A COMPREHENSIVE PROGRAM OF DIGITAL CASE FINDING AND LINKAGE TO CARE ACROSS A LARGE URBAN HEALTHCARE SYSTEM - (11/13/20)   Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes - (11/13/20)   INCIDENCE OF LIVER-RELATED EVENTS IN 647 DAA-CURED HCV CIRRHOTIC PATIENTS: A 5-YEAR SINGLE-CENTER STUDY - (11/13/20)   Provision of Hepatitis C Care in a Federally Qualified Health Center during the COVID-19 Pandemic - (11/13/20)   Clinically important changes in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a large real-world setting- results from the German Hepatitis C-Registry (DHC-R) - (11/13/20)   Impact of the COVID19 pandemic lockdown in an externalized HCV linkage to care model focusing on PWID patients with ongoing high risk practices - (11/13/20)   Effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic HCV infection and mental health disorders: real-world care management from 8 countries - (11/13/20)   REAL-WORLD ANALYSIS OF BIRTH COHORT HEPATITIS C ANTIBODY PREVALENCE IN ONTARIO, CANADA - (11/13/20)   An Integrated Community-Based Approach to Manage and Eliminate Hepatitis C in Vulnerable Populations: The Ontario Hepatitis C Teams Experience - (11/13/20)   The Impact of COVID-19 on an Outpatient HCV Testing and Treatment Program in New York City: A Natural Experiment In Sudden HCV Treatment Simplification - (11/13/20)